CA-DEXERIALS
22.3.2024 02:31:27 CET | Business Wire | Press release
Dexerials Corporation, (TOKYO: 4980) (Headquarters: Shimotsuke-shi, Tochigi, Representative Director and President: Yoshihisa Shinya, hereinafter “Dexerials”), which provides leading-edge technologies, materials, and devices for smartphones, automobiles, and other products, announces that the name of the integrated company to be created under Dexerials Precision Components Corporation (Headquarters: Tome-shi, Miyagi, Hereinafter “DXPC”) and Kyoto Semiconductor Co., Ltd. (Headquarters: Shimotsuke-shi, Tochigi, hereinafter “Kyoto Semiconductor”) has been determined as Dexerials Photonics Solutions Corporation (hereinafter “DXPS”), a consolidated subsidiary of Dexerials in Japan, and that DXPS will commence operation on April 1, 2024. In accordance with Dexerials’ news release on July 31, 2023, entitled Notice Regarding Launch of Integrated Company to Lead Growth in the Photonics Domain, preparations for a launch of the integrated company between DXPC and Kyoto Semiconductor had been made.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321222931/en/
Change in sales structure after the launch of DXPS (Graphic: Business Wire)
The profile of DXPS is as follows.
Profile of the integrated company
Corporate name |
Dexerials Photonics Solutions Corporation |
Head office |
Shimotsuke-shi, Tochigi |
Offices |
Eniwa Operation, Kamisunagawa Operation and Tome Operation |
Date of inauguration |
April 1, 2024 |
Share capital |
100 million yen |
Representative (planned) |
Kazuya Hayashibe, Representative Director and President |
Business |
Development, production and production management of optical semiconductors, optical devices and semiconductor-composite devices (photonics products) |
Dexerials Group will support DXPS in developing and providing solutions essential to the evolution of technologies in the photonics domain, aiming to increase efficiency in society. In so doing, the Group will help build a sustainable society, while aiming to achieve continuous growth and higher corporate value.
DXPS will develop and manufacture** microdevices and optical semiconductor device products that have been operated by DXPC and Kyoto Semiconductor. Dexerials will sell them to customers as its photonics products.
Dexerials and Kyoto Semiconductor will participate as an exhibitor at the OFC 2024 trade show that will take place at the San Diego Convention Center in San Diego in the United States from Tuesday, March 26 to Thursday, March 28. We cordially invite visitors to the exhibition to drop by our booth.
Comment from Kazuya Hayashibe, Representative Director and President (planned), DXPS
The Dexerials Group has been effectively combining technologies with the knowledge possessed by its human resources to offer materials and solutions indispensable to electronics and automobiles, aiming to link them to the evolution of digital technologies.
In the future, artificial intelligence (AI), Internet of things (IoT), next-generation communication and other new technologies will have increasing opportunities to play significant roles in boosting the efficiency of society for solving social issues. It is hence anticipated that optical semiconductors and the photonics solutions that support them will also have greater roles to play.
DXPS will lead the Dexerials Group’s business growth in the photonics domain. It will combine the optical semiconductor technologies cultivated by Kyoto Semiconductor, one of its predecessors, with the Dexerials Group’s technologies of controlling light and electricity to create unprecedented photonics solutions and to help resolve social issues. This will be the reason for its existence and it will tackle its work with a strong determination.
Dexerials and Kyoto Semiconductor will showcase their products and present the integrated company, DXPS, in their booth at the OFC 2024 exhibition that will start on March 26 in San Diego in the United States. We cordially invite visitors to the exhibition to drop by our booth. We look forward to seeing you at San Diego.
Change in sales structure after the launch of DXPS
Please see the diagram.
(Notes) |
* DXPC, Kyoto Semiconductor and DXPS are wholly owned subsidiaries of Dexerials Corporation. |
|
** After the launch of DXPS, OSDC will continue to manufacture microdevices under contract. |
|
*** Photonics products correspond to products that have been handled by DXPC and Kyoto Semiconductor. |
Participation in the OFC 2024 exhibition in San Diego, USA
OFC 2024 Exhibition
Date: Tuesday, March 26, 2024 to Thursday, March 28, 2024
Venue: San Diego Convention Center (San Diego, USA)
Stand number: 3814
Official website: https://www.ofcconference.org/en-us/home/
Products to be displayed
1. Optical semiconductor
2. Inorganic waveplate
3. Smart precision Adhesive
4. Anisotropic Conductive Film (ACF)
About Dexerials Corporation https://www.dexerials.jp/en/
Dexerials Corporation is a manufacturer providing functional materials for use in smartphones, automobiles and other domains in accordance with its corporate vision, Value Matters - Unprecedented innovation, unprecedented value. On a global scale, Dexerials Corporation manufactures and markets Anisotropic Conductive Film (ACF), optical elastic resin (SVR), anti-reflection film, surface mounted type fuses, industrial adhesives, double- and single-sided tapes and other electronic parts, junction materials, optical materials, and many other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321222931/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom